Study Comparing Two Different Tablet Formulations Of Bosutinib Under Fed Conditions
Phase 1
Completed
- Conditions
- Healthy
- Interventions
- Drug: SKI-606 (Bosutinib)
- Registration Number
- NCT01080365
- Lead Sponsor
- Wyeth is now a wholly owned subsidiary of Pfizer
- Brief Summary
Study comparing 2 formulations of bosutinib in healthy subjects.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 31
Inclusion Criteria
- Men or women of nonchildbearing potential age 18 to 50 years
Exclusion Criteria
- Any clinically significant medical condition
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- CROSSOVER
- Arm && Interventions
Group Intervention Description 1 SKI-606 (Bosutinib) Commercial Tablet 2 SKI-606 (Bosutinib) Clinical Tablet
- Primary Outcome Measures
Name Time Method Pharmacokinetics, as measured by Cmax, AUC, tmax, t1/2 2 weeks
- Secondary Outcome Measures
Name Time Method
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
What are the molecular mechanisms of bosutinib in targeting BCR-ABL and SRC kinases in CML treatment?
How does bosutinib compare to imatinib in terms of efficacy and safety for chronic myeloid leukemia patients?
What biomarkers are associated with response to bosutinib in tyrosine kinase inhibitor therapy?
What are the common adverse events reported with bosutinib use in clinical trials and how are they managed?
What are the current combination therapies involving bosutinib for CML and Ph+ ALL treatment?
Trial Locations
- Locations (1)
Pfizer Investigational Site
🇺🇸Tacoma, Washington, United States
Pfizer Investigational Site🇺🇸Tacoma, Washington, United States